Madrigal Pharmaceuticals (MDGL)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$1.54 (-0.48%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Key Insights

Critical company metrics and information
  • Share Price

    $318.52
  • Market Cap

    $6.95 Billion
  • Total Outstanding Shares

    21.81 Million Shares
  • Total Employees

    376
  • Dividend

    No dividend
  • IPO Date

    February 6, 2007
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    http://www.madrigalpharma.com

Historical Stock Splits

If you bought 1 share of MDGL before July 25, 2016, you'd have 0.03 shares today.
Execution DateSplit Amount
July 25, 20161-for-35 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$175.63 Million
Net Cash Flow From Investing Activities, Continuing$-588.56 Million
Net Cash Flow From Operating Activities, Continuing$-431.02 Million
Net Cash Flow From Financing Activities$1.20 Billion
Net Cash Flow From Operating Activities$-431.02 Million
Net Cash Flow From Investing Activities$-588.56 Million
Net Cash Flow, Continuing$175.63 Million
Net Cash Flow From Financing Activities, Continuing$1.20 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Income/Loss$-548.05 Million
Diluted Earnings Per Share$-24.99
Income/Loss From Continuing Operations Before Tax$-518.67 Million
Net Income/Loss$-518.67 Million
Revenues$76.81 Million
Interest Expense, Operating$15.14 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Average Shares$40.81 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$624.87 Million
Basic Earnings Per Share$-24.99
Income/Loss From Continuing Operations After Tax$-518.67 Million
Basic Average Shares$40.81 Million
Net Income/Loss Available To Common Stockholders, Basic$-518.67 Million
Net Income/Loss Attributable To Parent$-518.67 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Fixed Assets$2.27 Million
Other Current Assets$51.32 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Liabilities$102.20 Million
Equity$777.15 Million
Assets$1.07 Billion
Accounts Payable$45.97 Million
Noncurrent Liabilities$118.26 Million
Current Assets$1.06 Billion
Cash$1.00 Billion
Long-term Debt$117.09 Million
Inventory$8.71 Million
Current Liabilities$177.85 Million
Wages$29.68 Million
Equity Attributable To Parent$777.15 Million
Liabilities$296.11 Million
Noncurrent Assets$9.60 Million
Liabilities And Equity$1.07 Billion
Other Non-current Assets$7.33 Million
Other Non-current Liabilities$1.18 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.